| Cancer type | Cell line | Effects | Reference |
| Breast | MCF-7 | Cytotoxicity | [70] | | Activation of caspase-3, apoptosis | [71] | | Inactivation of NF-ĸB pathway and downregulation of its genes | [72] | MDA-MB-231 | Cytotoxicity | [73] | | Activation of caspase-3 | [71] | 4T1 | Downregulation of MMP-9 and VEGF, upregulation of IL-2 and IL-10, antitumour | [74] |
| Cervical | CaSki | Upregulation of has-miR-138, has-miR-210, and has-miR-744 | [75] | CaSki and SiHa | Overexpression of RSU1, antiproliferation, apoptosis | [76] | | Downregulation of miR-210, upregulation of SMAD4 | [77] |
| Colon | SW-480 | Cell cycle arrest, upregulation of p21, reduction of cyclin D, antiproliferation | [78] | Colo 320 | Antiproliferation, apoptosis | [79] |
| Lung | A549 | Inactivation of NF-ĸB pathway and downregulation of its genes, cytotoxicity, antitumour | [80] | | Induced prosurvival autophagy through Beclin-1-independent pathway | [81] |
| Prostate | PC-3 | Inactivation of NF-ĸB pathway and downregulation of its genes, cytotoxicity, antitumour | [62] | | Downregulation of CXCR4, VEGF, p65, and Ki-67, antitumour | [74] | | Antiproliferation, antimigration, antiadhesion, downregulation of Src, CD31, VEGF | [82] |
| Oral | HSC-4 | Apoptosis, antimigration, antitumour, downregulation FasL, Bim, NF-κB, COX-2 and cyclin D1 | [83] |
|
|